Regeneron presents positive data from PANORAMA trial

Patients in the PANORAMA trial who underwent early intervention with Eylea experienced improvements in diabetic retinopathy severity, and the majority experienced prevention of serious vision-threatening complications.
Trial investigator Charles C. Wykoff, MD, PhD, presented the 1-year results of the phase 3 trial at Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2019 symposium in Miami. The double-masked, randomized trial included patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) treated with Eylea (aflibercept, Regeneron)

Full Story →